Clinical Trial

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-01-14; most recent amendment 2025-09-29.
Status change: Not Yet Recruiting → Recruiting 2022-06-23
Trial Details
NCT Number NCT05211570
Lead Sponsor AB Science
Conditions Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
Enrollment 78 participants
Start Date 2022-06-01
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-02